MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
327.31
-1.38
-0.42%
After Hours: 327.00 -0.31 -0.09% 19:46 12/31 EST
OPEN
328.69
PREV CLOSE
328.69
HIGH
329.50
LOW
327.06
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
346.38
52 WEEK LOW
248.95
MARKET CAP
176.25B
P/E (TTM)
25.30
1D
5D
1M
3M
1Y
5Y
1D
XLV, ABT, AMGN, GILD: Large Outflows Detected at ETF
NASDAQ · 12/31/2025 17:30
How To YieldBoost Amgen To 5.5% Using Options
NASDAQ · 12/31/2025 17:18
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report
Seeking Alpha · 12/31/2025 13:22
1 Safe-and-Steady Stock to Keep an Eye On and 2 We Question
Barchart · 12/31/2025 07:36
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
Seeking Alpha · 12/30/2025 20:37
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
NASDAQ · 12/30/2025 18:22
Can Amgen's MariTide Take on Leaders in the Obesity Space?
NASDAQ · 12/30/2025 16:05
AMGEN INC <AMGN.O>: ARGUS RESEARCH RAISES TARGET PRICE TO $360 FROM $310
Reuters · 12/30/2025 12:16
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.